Published date: 23 July 2020

Last edited date: 25 November 2020

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 1 September 2020, 12am

Contract summary

Industry

  • Pharmaceutical products - 33600000

  • Various medicinal products - 33690000

Location of contract

East Midlands, East of England, London, North East, North West, South East, South West, West Midlands, Yorkshire and the Humber

Value of contract

£0 to £75,000,000

Procurement reference

CF-0003600D0O000000rwimUAA2

Published date

23 July 2020

Closing date

1 September 2020

Closing time

12am

Contract start date

1 December 2020

Contract end date

30 November 2022

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

The NHS Commissioning Board (operating under the name of NHS England and NHS Improvement) looks to establish an NHS Framework agreement (on behalf of NHS Trusts) for the supply of drugs licensed specifically to target epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.


Ref: Tender C1485 Period of framework: 1st December 2020* to 30th November 2022 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 36 months)

All documents can be found at:health.atamis.co.uk

More information

Previous notice about this procurement

NHS Framework Colorectal Cancer Drugs (See description below)

  • Opportunity
  • Published 23 July 2020

About the buyer

Contact name

Liz Fleetwood

Address

80 London Road
London
SE1 6LH
GB

Email

liz.fleetwood1@nhs.net